Mycophenolate mofetil in the treatment of lupus nephritis, in patients with failure, intolerance or relapses after treatment with steroids and cyclophosphamide;Micofenolato mofetil en el tratamiento de la nefritis lúpica en pacientes con fracaso, intolerancia o recidivas tras tratamiento con esteroides y ciclofosfamida

Nefrologia

Volumn 27, Issue 4, 2007, Pages 459-465

  Suría González, Santiago ^a   Checa, M D ^a  

^a HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

Cyclophosphamide; Lupus nephritis; Mycophenolate mofetil; Steroids; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT FAILURE;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RECURRENCE; STEROIDS; TREATMENT FAILURE;

EID: 38449101205     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Fine MD: Pharmacological Therapy of Lupus Nephritis. JAMA 293: 3053-3060, 2005.
2. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisona only. Arthritis Rheum 34: 945-950, 1991.
3. Boumpas DT, Austin HA III, Vaughan EM y cols.: Controlled trial of pulse methyl-prednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992.
4. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP: The Benefit of Early Treatmen with Immunosuppressive Agents in Lupus Nephritis. J Rheumatol 21: 2046-2051, 1994.
5. Dooley MA, Cosío FG, Nachman PH y cols.: Therapy in Lupus Nephritis: Clinical Observations. J Am Soc Nephrol 10: 833-839, 1999.
6. Dooley MA, Falk RJ: Immunosuppressive therapy of lupus nephritis. Lupus 7: 630-634, 1998.
7. Jayne D: Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens 8: 563-567, 1999.
8. Zandman-Goddard G, Shoenfeld Y: Mycophenolate mofetil in animal models of autoimmune disease. Lupus 14:s12-s16, 2005.
9. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC: Treatment of Diffuse Proliferative Lupus Nephritis: a Meta-Analysis of Randomized Controlled Trials. Am J Kidney Dis 43: 197-208, 2004.
10. Gilcklich D, Acharya A: Mycophenolate Mofetil Therapy for Lupus Nephritis Refractory to Intravenous Cyclophosphamide. Am J Kidney Dis 32: 318-322, 1998.
11. Pisoni CN, Karim Y, Cuadrado MJ: Mycophenolate mofetil and lupus erythematosus an overview. Lupus 14: s9-s11, 2005.
12. Chan TM, Li FK, Tang CSO y cols.: Efficacy of Mycophenolate Mophetil in Patients with Diffuse Proliferative Lupus Nephritis. N Engl J Med 343: 1156-1162, 2000.
13. Chan TM: Lupus nephritis: induction therapy. Lupus 14: s27-s32, 2005.
14. Van Bruggen MCJ, Walgreen B, Rijke TPM, Berden JHM: Attenuation of Murine Lupus Nephritis by Mycophenolate Mofetil. J Am Soc Nephrol 9: 1407-1415, 1998.
15. Ramos MA, Piñera C, Setién MA y cols.: Modulation of autoantibody-production by development of SLE in (NZBxNZW) F1 mice. Nephrol Dial Transplant 18: 878-883, 2003.
16. Austin HA, Balow JE: Treatment of Lupus Nephritis. Semin Nephrol 20: 265-276, 2000.
17. Weening JJ, D'Agati VD, Schwartz MM y cols.: The classification of glomerulonephritis in systemic lupus erythematous revisited. Kidney Int 65: 521-530, 2004.
18. Álvarez L, Rivera R, Gil CM, Jiménez del Cerro LA, Olivares J. Micofenolato mofetil en la nefritis lúpica. Nefrología 22 (1): 24-32, 2002.
19. Kingdon EJ, McLean AG, Psimeou E y cols.: The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 10: 606-611, 2001.
20. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM: Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 43: 377-380, 2004.
21. Ferro ML, Karim MY, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GRV: Mycophenolate mofetil: a potential treatment for reducing proteinuria associated with membranous lupus nephritis. Arthritis Rheum 48: S588, 2003.
22. Karim MY, Pisoni CN, Ferro L y cols.: Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology 44: 1317-1321, 2005.
23. Karim MY, Alba P, Cuadrado M-J y cols.: Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41: 876-882, 2002.
24. Pisoni CN, Sánchez FJ, Karim Y y cols.: Mycophenolate Mofetil in Systemic Lupus Erythematosus: Efficacy and Tolerability in 86 Patients. J Rhematol 32: 1047-1052, 2005.
25. Houssiau FA, Vasconcelos C, D'Cruz D y cols.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002.
26. Contreras G, Pardo V, Leclercq B y cols.: Sequential Therapies for Proliferative Lupus Nphritis. N Engl J Med 350: 971-980, 2004.
27. Ginzler EM, Aranow C, Buyon J y cols.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (21): 2219-2228, 2005.
28. Ginzler EM, Aranow C, Merril JT, Orloff K, Henry D: Toxicity and tolerability of mycophenolate mofetil (MMF) vs, intravenous cyclophosphamide (IVC) in a multicenter trial as induction therapy for lupus nephritis (LN). Arthritis Rheum 48: S586, 2003.
29. Chan TM, Tse KC, Tang CSO, Mok MY, Li FK: Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis. J Am Soc Nephrol 16: 1076-1084, 2005.